Enhancement of the anti-melanoma response of Hu14.18K322A by αcD40 + CpG

Cancer Immunology, Immunotherapy

Volumn 62, Issue 4, 2013, Pages 665-675

  Alderson, Kory L ^a   Luangrath, Mitchell ^a   Elsenheimer, Megan M ^a   Gillies, Stephen D ^b   Navid, Fariba ^c   Rakhmilevich, Alexander L ^a,d   Sondel, Paul M ^a,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Provenance Biopharmaceuticals Corp   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Antibody dependent cellular cytotoxicity (ADCC); CD40; GD2; Macrophage; Melanoma; NK cell

Indexed keywords

ANTINEOPLASTIC AGENT; CD40 LIGAND MONOCLONAL ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE 1826; HU14.18K322A MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SIZE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; IN VITRO STUDY; INNATE IMMUNITY; MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; T CELL DEPLETION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD40; GANGLIOSIDES; IMMUNIZATION, PASSIVE; KILLER CELLS, NATURAL; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, SCID; MYELOID CELLS; OLIGODEOXYRIBONUCLEOTIDES;

EID: 84877816431     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1372-8     Document Type: Article

References (46)

1. Koehn TA, Trimble LL, Alderson KL, Erbe AK, McDowell KA, Grzywacz B, Hank JA, Sondel PM (2012) Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Front Pharmacol 3:91. doi: 10.3389/fphar.2012.00091
2. Alderson KL, Sondel PM (2011) Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol 2011:379123. doi: 10.1155/2011/379123
3. Yamane BH, Hank JA, Albertini MR, Sondel PM (2009) The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin Investig Drugs 18(7):991-1000. doi: 10.1517/13543780903048911
4. Sorkin LS, Otto M, Baldwin WM 3rd, Vail E, Gillies SD, Handgretinger R, Barfield RC, Ming YuH, Yu AL (2010) Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain 149(1):135-142. doi: 10.1016/j.pain.2010.01.024
5. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278(5):3466-3473. doi: 10.1074/jbc.M210665200
6. Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, Lewis G, Ladenstein R, Lode HN (2005) Anti-neuroblastoma effect of ch 14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 42(11):1311-1319. doi: 10.1016/j.molimm.2004.12.018
7. Buhtoiarov IN, Lum HD, Berke G, Sondel PM, Rakhmilevich AL (2006) Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol 176(1):309-318
8. Buhtoiarov IN, Sondel PM, Eickhoff JC, Rakhmilevich AL (2007) Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology 120(3):412-423. doi: 10.1111/j.1365-2567.2006.02517.x
9. Buhtoiarov IN, Lum H, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL (2005) CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol 174(10):6013-6022
10. Turner JG, Rakhmilevich AL, Burdelya L, Neal Z, Imboden M, Sondel PM, Yu H (2001) Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J Immunol 166(1):89-94
11. Straten PT, Guldberg P, Seremet T, Reisfeld RA, Zeuthen J, Becker JC (1998) Activation of preexisting T cell clones by targeted interleukin 2 therapy. Proc Natl Acad Sci USA 95(15):8785-8790
12. Van Rooijen N, Sanders A (1994) Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174(1-2):83-93
13. Dyall R, Vasovic LV, Clynes RA, Nikolic-Zugic J (1999) Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor. Eur J Immunol 29(1):30-37. doi: 10.1002/(SICI)1521-4141(199901)29: 01<30:AID-IMMU30>3.0.CO;2-D
14. Hank JA, Albertini MR, Schiller J, Sondel PM (1993) Activation of multiple effector mechanisms to enhance tumor immunotherapy. J Immunother Emphasis Tumor Immunol 14(4):329-335
15. Ralph P, Nakoinz I (1984) Cooperation of IgG monoclonal antibodies in macrophage antibody-dependent cellular cytotoxicity (ADCC) to tumor targets. J Leukoc Biol 35(1):131-139
16. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199(12):1659-1669. doi: 10.1084/jem.20040119
17. Roder JC (1979) The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function. J Immunol 123(5):2168-2173
18. Roder JC, Lohmann-Matthes ML, Domzig W, Wigzell H (1979) The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect. J Immunol 123(5):2174-2181
19. Yokoyama WM, Kim S, French AR (2004) The dynamic life of natural killer cells. Annu Rev Immunol 22:405-429. doi: 10.1146/annurev.immunol.22.012703. 104711
20. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM (2010) Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 70(23):9554-9561. doi: 10.1158/0008-5472.CAN-10-2211
21. Joshi T, Ganesan LP, Cheney C, Ostrowski MC, Muthusamy N, Byrd JC, Tridandapani S (2009) The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma. PLoS ONE 4(1):e4208. doi: 10.1371/journal.pone.0004208
22. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M, Golay J (2009) M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 182(7):4415-4422. doi: 10.4049/jimmunol.0713732
23. Oflazoglu E, Stone IJ, Brown L, Gordon KA, van Rooijen N, Jonas M, Law CL, Grewal IS, Gerber HP (2009) Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer 100(1):113-117. doi: 10.1038/sj.bjc.6604812
24. Abes R, Gelize E, Fridman WH, Teillaud JL (2010) Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116(6):926-934. doi: 10.1182/blood-2009-10-248609
25. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV (1998) Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 95(2):652-656
26. Fridman WH, Teillaud JL, Sautes-Fridman C, Pages F, Galon J, Zucman-Rossi J, Tartour E, Zitvogel L, Kroemer G (2011) The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Front Immunol 2:66. doi: 10.3389/fimmu.2011.00066
27. Imboden M, Murphy KR, Rakhmilevich AL, Neal ZC, Xiang R, Reisfeld RA, Gillies SD, Sondel PM (2001) The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res 61(4):1500-1507
28. Rakhmilevich AL, Baldeshwiler MJ, Van De Voort TJ, Felder MA, Yang RK, Kalogriopoulos NA, Koslov DS, Van Rooijen N, Sondel PM (2012) Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer Immunol Immunother. doi: 10.1007/s00262-012-1236-2
29. Liu W, Xiao X, Demirci G, Madsen J, Li XC (2012) Innate NK cells and macrophages recognize and reject allogeneic nonself in vivo via different mechanisms. J Immunol 188(6):2703-2711. doi: 10.4049/jimmunol.1102997
30. Saddawi-Konefka R OST, Vermi W, et al. (2012) Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Immunol Meet Abstr Suppl 188 (162.3)
31. Roda JM, Parihar R, Carson WE 3rd (2005) CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 175(3):1619-1627
32. Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S, Jones NB, Roda JM, Mani A, Parihar R, Karpa V, Papenfuss TL, LaPerle KM, Biller E, Lehman A, Chaudhury AR, Jarjoura D, Burry RW, Carson WE 3rd (2011) IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-gamma production. J Immunol 186(6):3401-3409. doi: 10.4049/jimmunol.1000328
33. Xin L, Shelite TR, Gong B, Mendell NL, Soong L, Fang R, Walker DH (2012) Systemic treatment with CpG-B after sublethal rickettsial infection induces mouse death through indoleamine 2,3-dioxygenase (IDO). PLoS ONE 7(3):e34062. doi: 10.1371/journal.pone.0034062PONE-D-11-21888
34. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ (1997) Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89(8):2994-2998
35. Ballas ZK, Rasmussen WL, Krieg AM (1996) Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157(5):1840-1845
36. van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ (2003) CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res 63(17):5595-5600
37. Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS (2009) Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 146(3):282-291. doi: 10.1111/j.1365-2141.2009.07773.x
38. Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM (2009) Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. J Immunother 32(6):622-631. doi: 10.1097/CJI.0b013e3181ab23f1
39. Tsai CY, Lu SL, Hu CW, Yeh CS, Lee GB, Lei HY (2012) Size-dependent attenuation of TLR9 signaling by gold nanoparticles in macrophages. J Immunol 188(1):68-76. doi: 10.4049/jimmunol.1100344
40. Buhtoiarov IN, Rakhmilevich AL, Lanier LL, Ranheim EA, Sondel PM (2009) Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules. J Immunol 182(4):1940-1953. doi: 10.4049/jimmunol.0800443
41. Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL (2006) In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol 79(6):1181-1192. doi: 10.1189/jlb.0405191
42. Rakhmilevich AL, Buhtoiarov IN, Malkovsky M, Sondel PM (2008) CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. Cancer Immunol Immunother 57(8):1151-1160. doi: 10.1007/s00262-007-0447-4
43. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024):1612-1616. doi: 10.1126/science.1198443
44. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324-1334. doi: 10.1056/NEJMoa0911123
45. Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM (2010) Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol 28(33):4969-4975. doi: 10.1200/JCO.2009.27.8861
46. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, Berthold F (2004) Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 22(17):3549-3557. doi: 10.1200/JCO.2004.08.14322/17/3549